• 8265 Citations
  • 37 h-Index
1987 …2024

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Outputs

2020

Melphalan exposure and outcome in obese and non-obese adults with myeloma. A study of pharmacokinetics and pharmacodynamics

Nath, C. E., Trotman, J., Nivison-Smith, I., Gurney, H., Zeng, L., Presgrave, P., Tiley, C., Joshua, D., Kerridge, I., McLachlan, A. J. & Shaw, P. J., 21 Feb 2020, In : Bone Marrow Transplantation.

Research output: Contribution to journalLetter

2019

A potent liver-mediated mechanism for loss of muscle mass during androgen deprivation therapy

Lam, T., McLean, M., Hayden, A., Poljak, A., Cheema, B., Gurney, H., Stone, G., Bahl, N., Reddy, N., Shahidipour, H. & Birzniece, V., 1 May 2019, In : Endocrine Connections. 8, 5, p. 605-615 11 p.

Research output: Contribution to journalArticle

Open Access
File
2 Downloads (Pure)

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Rini, B. I., Powles, T., Atkins, M. B., Escudier, B., McDermott, D. F., Suarez, C., Bracarda, S., Stadler, W. M., Donskov, F., Lee, J. L., Hawkins, R., Ravaud, A., Alekseev, B., Staehler, M., Uemura, M., De Giorgi, U., Mellado, B., Porta, C., Melichar, B., Gurney, H. & 12 others, Bedke, J., Choueiri, T. K., Parnis, F., Khaznadar, T., Thobhani, A., Li, S., Piault-Louis, E., Frantz, G., Huseni, M., Schiff, C., Green, M. C. & Motzer, R. J., 15 Jun 2019, In : The Lancet. 393, 10189, p. 2404-2415 12 p.

Research output: Contribution to journalArticle

63 Citations (Scopus)

Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma

Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Negrier, S., Uemura, M., Lee, J. L., Vasiliev, A., Miller, W. H., Gurney, H., Schmidinger, M., Larkin, J., Atkins, M. B., Bedke, J., Alekseev, B., Wang, J. & 8 others, Mariani, M., Robbins, P. B., Chudnovsky, A., Fowst, C., Hariharan, S., Huang, B., Di Pietro, A. & Choueiri, T. K., 21 Mar 2019, In : New England Journal of Medicine. 380, 12, p. 1103-1115 13 p.

Research output: Contribution to journalArticle

202 Citations (Scopus)

Clinical concepts for cabazitaxel in the management of metastatic castration-resistant prostate cancer

Al-Mansouri, L. & Gurney, H., 1 Dec 2019, In : Asia-Pacific Journal of Clinical Oncology. 15, 6, p. 288-295 8 p.

Research output: Contribution to journalReview article

Continuing cabazitaxel beyond 10 cycles for metastatic castrate-resistant prostate cancer: is there a benefit?

Al-Mansouri, L., Arasaratnam, M. & Gurney, H., 14 Jun 2019, In : European Journal of Hospital Pharmacy.

Research output: Contribution to journalArticle

Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer

Arasaratnam, M., Crumbaker, M., Bhatnagar, A., McKay, M. J., Molloy, M. P. & Gurney, H., Jul 2019, In : Cancer Chemotherapy and Pharmacology. 84, 1, p. 139-146 8 p.

Research output: Contribution to journalArticle

1 Citation (Scopus)

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Motzer, R. J., Rini, B. I., McDermott, D. F., Arén Frontera, O., Hammers, H. J., Carducci, M. A., Salman, P., Escudier, B., Beuselinck, B., Amin, A., Porta, C., George, S., Neiman, V., Bracarda, S., Tykodi, S. S., Barthélémy, P., Leibowitz-Amit, R., Plimack, E. R., Oosting, S. F., Redman, B. & 19 others, Melichar, B., Powles, T., Nathan, P., Oudard, S., Pook, D., Choueiri, T. K., Donskov, F., Grimm, M. O., Gurney, H., Heng, D. Y. C., Kollmannsberger, C. K., Harrison, M. R., Tomita, Y., Duran, I., Grünwald, V., McHenry, M. B., Mekan, S., Tannir, N. M. & CheckMate 214 Investigators, 1 Oct 2019, In : The Lancet Oncology. 20, 10, p. 1370-1385 16 p.

Research output: Contribution to journalArticle

19 Citations (Scopus)

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Fradet, Y., Bellmunt, J., Vaughn, D. J., Lee, J. L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D. I., Culine, S., Sternberg, C. N., Nam, K., Frenkl, T. L., Perini, R. F., De Wit, R. & Bajorin, D. F., 1 Jun 2019, In : Annals of Oncology. 30, 6, p. 970-976 7 p., mdz127.

Research output: Contribution to journalArticle

Open Access
File
11 Citations (Scopus)
10 Downloads (Pure)

Tamoxifen-induced severe hot flashes and endoxifen levels: is dose reduction a safe and effective strategy?

Lee, C. I., Fox, P., Balakrishnar, B., Balleine, R. L., Gao, B., Provan, P., Coulter, S., Liddle, C., Hui, R., Wong, M., Gurney, H. & Wilcken, N., 1 Aug 2019, In : Breast. 46, p. 52-57 6 p.

Research output: Contribution to journalArticle

2018

Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment

Attard, G., Borre, M., Gurney, H., Loriot, Y., Andresen-Daniil, C., Kalleda, R., Pham, T., Taplin, M. E. & on behalf of PLATO collaborators, 1 Sep 2018, In : Journal of Clinical Oncology. 36, 25, p. 2639-2646 8 p.

Research output: Contribution to journalArticle

Open Access
File
23 Citations (Scopus)
8 Downloads (Pure)

Cardiovascular toxicity of targeted therapies for cancer: a protocol for an overview of systematic reviews

Van Leeuwen, M. T., Luu, S., Gurney, H., Brown, M. R., Webber, K., Pearson, S-A., Hunt, L. & Vajdic, C. M., 1 Jun 2018, In : BMJ Open. 8, 6, p. 1-6 6 p., e021064.

Research output: Contribution to journalArticle

Open Access
File
5 Downloads (Pure)

Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer

Gao, B., Lu, Y., Nieuweboer, A. J. M., Xu, H., Beesley, J., Boere, I., De Graan, A. J. M., De Bruijn, P., Gurney, H., Kennedy, C. J., Chiew, Y. E., Johnatty, S. E., Beale, P., Harrison, M., Luccarini, C., Conroy, D., Mathijssen, R. H. J., Harnett, P. R., Balleine, R. L., Chenevix-Trench, G. & 2 others, MacGregor, S. & De Fazio, A., 1 Dec 2018, In : Scientific Reports. 8, 1, p. 1-10 10 p., 1508.

Research output: Contribution to journalArticle

Open Access
File
14 Downloads (Pure)

Health-related quality-of-life analysis from KEYNOTE-045: a phase III study of pembrolizumab versus chemotherapy for previously treated advanced urothelial cancer

Vaughn, D. J., Bellmunt, J., Fradet, Y., Lee, J. L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D. I., Culine, S., Sternberg, C. N., Mai, Y., Li, H., Perini, R. F., Bajorin, D. F. & de Wit, R., 1 Jun 2018, In : Journal of Clinical Oncology. 36, 16, p. 1579-1587 12 p.

Research output: Contribution to journalArticle

23 Citations (Scopus)

Nivolumab in the treatment of advanced renal cell carcinoma

Arasaratnam, M. & Gurney, H., Jul 2018, In : Future Oncology. 14, 17, p. 1679-1689 11 p., 29460635.

Research output: Contribution to journalArticle

1 Citation (Scopus)

Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma

Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., Powles, T., Donskov, F., Neiman, V., Kollmannsberger, C. K., Salman, P., Gurney, H., Hawkins, R., Ravaud, A., Grimm, M. O., Bracarda, S. & 13 others, Barrios, C. H., Tomita, Y., Castellano, D., Rini, B. I., Chen, A. C., Mekan, S., McHenry, M. B., Wind-Rotolo, M., Doan, J., Sharma, P., Hammers, H. J., Escudier, B. & CheckMate 214 Investigators, 5 Apr 2018, In : New England Journal of Medicine. 378, 14, p. 1277-1290 14 p.

Research output: Contribution to journalArticle

713 Citations (Scopus)

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

Powles, T., Motzer, R. J., Escudier, B., Pal, S., Kollmannsberger, C., Pikiel, J., Gurney, H., Rha, S. Y., Park, S. H., Geertsen, P. F., Gross-Goupil, M., Grande, E., Suarez, C., Markby, D. W., Arroyo, A., Dean, M., Choueiri, T. K. & George, D., 11 Sep 2018, In : British Journal of Cancer. 119, 6, p. 663-669 7 p.

Research output: Contribution to journalArticle

Open Access
File
12 Citations (Scopus)
66 Downloads (Pure)
5 Citations (Scopus)

Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia

Crumbaker, M., Guminski, A., Gurney, H., Sabanathan, D., Wong, S. & Pavlakis, N., Apr 2018, In : Asia-Pacific Journal of Clinical Oncology. 14, 2, p. e45-e49 5 p.

Research output: Contribution to journalArticle

2 Citations (Scopus)
2017

A Distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer

PRIMe Consortium, 15 Nov 2017, In : International Journal of Cancer. 141, 10, p. 2112-2120 9 p.

Research output: Contribution to journalArticle

12 Citations (Scopus)

Cabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access program

Parente, P., Ng, S., Parnis, F., Guminski, A. & Gurney, H., Dec 2017, In : Asia-Pacific Journal of Clinical Oncology. 13, 6, p. 391-399 9 p.

Research output: Contribution to journalArticle

3 Citations (Scopus)

CheckMate 025 randomized Phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma

Escudier, B., Sharma, P., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., Castellano, D., Gurney, H., Donskov, F., Peltola, K., Wagstaff, J., Gauler, T. C., Ueda, T., Zhao, H., Waxman, I. M., Motzer, R. J. & 1 others, CheckMate 025 Investigators, 2017, In : European Urology. 72, 6, p. 962-971 10 p.

Research output: Contribution to journalArticle

97 Citations (Scopus)

Communicating risk in active surveillance of localised prostate cancer: A protocol for a qualitative study

Rapport, F., Hogden, A., Gurney, H., Gillatt, D., Bierbaum, M., Shih, P. & Churruca, K., 1 Oct 2017, In : BMJ Open. 7, 10, p. 1-7 7 p., e017372.

Research output: Contribution to journalArticle

Open Access
File
6 Downloads (Pure)

Cure in advanced renal cell cancer: Is it an achievable goal?

Sabanathan, D., Park, J. J., Marquez, M., Francisco, L., Byrne, N. & Gurney, H., 1 Dec 2017, In : Oncologist. 22, 12, p. 1470-1477 8 p.

Research output: Contribution to journalArticle

3 Citations (Scopus)

Cytoreductive nephrectomy for metastatic renal cell carcinoma: inequities in access exist despite improved survival

Patel, M. I., Beattie, K., Bang, A., Gurney, H. & Smith, D. P., Oct 2017, In : Cancer Medicine. 6, 10, p. 2188–2193 6 p.

Research output: Contribution to journalArticle

Open Access
File
11 Citations (Scopus)
2 Downloads (Pure)

Dose considerations for anti-cancer drugs in metastatic prostate cancer

Crumbaker, M. & Gurney, H., 1 Aug 2017, In : Prostate. 77, 11, p. 1199-1204 6 p.

Research output: Contribution to journalReview article

3 Citations (Scopus)

Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring

Sabanathan, D., Zhang, A., Fox, P., Coulter, S., Gebski, V., Balakrishnar, B., Chan, M., Liddle, C. & Gurney, H., Aug 2017, In : Cancer Chemotherapy and Pharmacology. 80, 2, p. 385–393 9 p.

Research output: Contribution to journalArticle

7 Citations (Scopus)

e-TC: development and pilot testing of a web-based intervention to reduce anxiety and depression in survivors of testicular cancer

Heiniger, L. E., Smith, A. B., Olver, I., Grimison, P., Klein, B., Wootten, A., Abbott, J-A. M., Price, M. A., McJannett, M., Tran, B., Stockler, M. R., Gurney, H. & Butow, P. N., Nov 2017, In : European Journal of Cancer Care. 26, 6, p. 1-10 10 p., e12698.

Research output: Contribution to journalArticle

4 Citations (Scopus)

Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure

Rowland, A., van Dyk, M., Mangoni, A. A., Miners, J. O., McKinnon, R. A., Wiese, M. D., Rowland, A., Kichenadasse, G., Gurney, H. & Sorich, M. J., 2017, In : Expert Opinion on Drug Metabolism and Toxicology. 13, 1, p. 31-49 19 p.

Research output: Contribution to journalReview article

29 Citations (Scopus)

Metastatic chromophobe renal cell carcinoma treated with targeted therapies: a Renal Cross Channel Group study

Colomba, E., Le Teuff, G., Eisen, T., Stewart, G. D., Fife, K., Larkin, J., Biondo, A., Pickering, L., Srinivasan, A., Boyle, H., Derosa, L., Sternberg, C. N., Recine, F., Ralph, C., Saldana, C., Barthélémy, P., Bernhard, J. C., Gurney, H., Verhoest, G., Vauleon, E. & 11 others, Bigot, P., Berger, J., Pfister, C., Gravis, G., Rodier, J-M., Culine, S., Caty, A., Rolland, F., Priou, F., Escudier, B. & Albiges, L., 1 Jul 2017, In : European Journal of Cancer. 80, p. 55-62 8 p.

Research output: Contribution to journalArticle

3 Citations (Scopus)

Pembrolizumab as second-line therapy for advanced urothelial carcinoma

Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D. I., Culine, S., Sternberg, C. N., Mai, Y., Poehlein, C. H., Perini, R. F. & Bajorin, D. F., 16 Mar 2017, In : New England Journal of Medicine. 376, 11, p. 1015-1026 12 p.

Research output: Contribution to journalArticle

853 Citations (Scopus)

Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer

Lin, H-M., Mahon, K. L., Spielman, C., Gurney, H., Mallesara, G., Stockler, M. R., Bastick, P., Briscoe, K., Marx, G., Swarbrick, A. & Horvath, L. G., 11 Apr 2017, In : British Journal of Cancer. 116, 8, p. 1002-1011 10 p.

Research output: Contribution to journalArticle

Open Access
File
23 Citations (Scopus)
4 Downloads (Pure)

Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers

Hopkins, A. M., Rowland, A., Kichenadasse, G., Wiese, M. D., Gurney, H., McKinnon, R. A., Karapetis, C. S. & Sorich, M. J., 26 Sep 2017, In : British Journal of Cancer. 117, 7, p. 913-920 8 p.

Research output: Contribution to journalArticle

Open Access
File
55 Citations (Scopus)
1 Downloads (Pure)

Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025

Escudier, B., Motzer, R. J., Sharma, P., Wagstaff, J., Plimack, E. R., Hammers, H. J., Donskov, F., Gurney, H., Sosman, J. A., Zalewski, P. G., Harmenberg, U., McDermott, D. F., Choueiri, T. K., Richardet, M., Tomita, Y., Ravaud, A., Doan, J., Zhao, H., Hardy, H. & George, S., Sep 2017, In : European Urology. 72, 3, p. 368-376 9 p.

Research output: Contribution to journalArticle

89 Citations (Scopus)
2016

Case series: silent malignant spinal cord compression (MSCC) secondary to spinal epidural metastases (SEM) in castrate-resistant prostate cancer (CRPC)

Park, J., Sabanathan, D., Lau, A. & Gurney, H., 2016, In : Asia-Pacific Journal of Clinical Oncology. 12, Suppl. S4, p. 66-66 1 p.

Research output: Contribution to journalMeeting abstract

Case series: silent malignant spinal cord compression (MSCC) secondary to spinal epidural metastases (SEM) in castrate-resistant prostate cancer (CRPC)

Park, J. J., Sabanathan, D., Lau, A. & Gurney, H., 2016, In : Asia-Pacific Journal of Clinical Oncology. 12, Suppl. S3, p. 38-38 1 p.

Research output: Contribution to journalMeeting abstract

Differences in the patterns of anti-pd1 (PD1) toxicity between tumor streams

Sabanathan, D., Kong, B., Byrne, N., Wegener, V., Eslick, G., Nagrial, A., Hui, R., Kefford, R., Gurney, H. & Carlino, M. S., 2016, In : Asia-Pacific Journal of Clinical Oncology. 12, Suppl. S4, p. 68-68 1 p.

Research output: Contribution to journalMeeting abstract

Dose escalation of tamoxifen in patients with low endoxifen level: Evidence for therapeutic drug monitoring - The TADE study

Fox, P., Balleine, R. L., Lee, C., Gao, B., Balakrishnar, B., Menzies, A. M., Yeap, S. H., Ali, S. S., Gebski, V., Provan, P., Coulter, S., Liddle, C., Hui, R., Kefford, R., Lynch, J., Wong, M., Wilcken, N. & Gurney, H., 1 Jul 2016, In : Clinical Cancer Research. 22, 13, p. 3164-3171 8 p.

Research output: Contribution to journalArticle

28 Citations (Scopus)

High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation

Nath, C. E., Trotman, J., Tiley, C., Presgrave, P., Joshua, D., Kerridge, I., Kwan, Y. L., Gurney, H., McLachlan, A. J., Earl, J. W., Nivison-Smith, I., Zeng, L. & Shaw, P. J., Jul 2016, In : British Journal of Clinical Pharmacology. 82, 1, p. 149-159 11 p.

Research output: Contribution to journalArticle

17 Citations (Scopus)

Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Lawrence, N., Martin, A., Toner, G., Stockler, M., Buizen, L., Thomson, D., Gebski, V., Friedlander, M., Yeung, A., Wong, N., Gurney, H., Rosenthal, M., Singhal, N., Kichenadasse, G., Wong, S., Lewis, C., Vasey, P. & Grimison, P., 1 Dec 2016, In : Annals of oncology : official journal of the European Society for Medical Oncology. 27, 12, p. 2302-2303 2 p.

Research output: Contribution to journalLetter

1 Citation (Scopus)

MILGa-01-a first in human study assessing the safety and tolerability of chMIL-38 in prostate cancer

Sabanathan, D., Gurney, H., Gillatt, D., Trifunovic, M., Magnussen, J., Poursoltan, P., Shon, K. H. O., Walsh, B. J., Mazure, H., Velonas, V., Thurecht, K., Quach Truong, Wissmueller, S. & Campbell, D., Aug 2016, In : BJU international. 118, Suppl. 1, p. 14-15 2 p.

Research output: Contribution to journalMeeting abstract

Patterns and trends in the incidence of paediatric and adult germ cell tumours in Australia, 1982-2011

van Leeuwen, M. T., Gurney, H., Turner, J. J., Turner, S. L., Pearson, S. A., Laaksonen, M. A., Harnett, P., Balakrishnar, B., Sabanathan, D. & Vajdic, C. M., 1 Aug 2016, In : Cancer Epidemiology. 43, p. 15-21 7 p.

Research output: Contribution to journalArticle

5 Citations (Scopus)

Real-world experience of the feasibility and tolerability of the 2:1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia

Crumbaker, M., Gurney, H., Guminski, A., Wong, S., Sabanathan, D. & Pavlakis, N., Jul 2016, In : Asia-Pacific Journal of Clinical Oncology. 12, S3, p. 47 1 p., abs#209.

Research output: Contribution to journalMeeting abstract

Tactic: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer

Ferraro, D., Goldstein, D., O’Connell, R. L., Zalcberg, J. R., Sjoquist, K. M., Tebbutt, N. C., Grimison, P., McLachlan, S., Lipton, L. L., Vasey, P., Gebski, V. J., Aiken, C., Cronk, M., Ng, S., Karapetis, C. S., Shannon, J., Shannon, J., Tebbutt, N., Ng, S., Cronk, M. & 48 others, Karapetis, C., Sjoquist, K., Aiken, C., Do, V., Marschner, I., Friedlander, M., Gurney, H., Simes, J., Hague, W., O’Connell, R., Gebski, V., Aiken, C., Gorzeman, M., Pike, R., Miranda, K., Waring, P., Ferraro, D., Lau, D., Fox, S., Tebbutt, N., Liu, Y., Vasey, P., Wood, T., Cronk, M., Cocks, C., Simmons, K., Shannon, J., McCourt, J., Jefford, M., Hobinchet, A., Grimison, P., Mirco, B., Sagong, J., Ng, S., Dudukovic, S., Aghmesheh, M., Parker, S., Segelov, E., Ratnayake, L., McLachlan, S., Ranieri, N., Varma, S., Page, J., Heyer, E., Abdi, E., Chorlton, C., Lipton, L. & Wilkinson, L., 1 Aug 2016, In : Cancer Chemotherapy and Pharmacology. 78, 2, p. 361-367 7 p.

Research output: Contribution to journalArticle

9 Citations (Scopus)

Tamoxifen, CYP2D6 and endoxifen in the treatment of hormone sensitive breast cancer: demystifying the connections

Lee, C. I. & Gurney, H., 1 Nov 2016, In : Cancer Forum. 40, 3, p. 4-10 7 p.

Research output: Contribution to journalArticle

2 Citations (Scopus)

The effect of pulmonary function testing on bleomycin dosing in germ cell tumours

Roncolato, F. T., Chatfield, M., Houghton, B., Toner, G., Stockler, M., Thomson, D., Friedlander, M., Gurney, H., Rosenthal, M., Grimison, P. & The Australian and New Zealand Urogenital Prostate Cancer Trials Group (ANZUP), 1 Aug 2016, In : Internal Medicine Journal. 46, 8, p. 893-898 6 p.

Research output: Contribution to journalArticle

7 Citations (Scopus)

The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study

Smith, A. B., Butow, P., Olver, I., Luckett, T., Grimison, P., Toner, G. C., Stockler, M. R., Hovey, E., Stubbs, J., Turner, S., Hruby, G., Gurney, H., Alam, M., Cox, K. & King, M. T., 1 Apr 2016, In : Journal of Cancer Survivorship. 10, 2, p. 223-233 11 p.

Research output: Contribution to journalArticle

30 Citations (Scopus)
2015

CheckMate 025: a randomized, open-label, phase Ill study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC)

Motzer, R. J., Escudier, B., Mcdermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., Castellano, D., Gurney, H., Donskov, F., Bono, P., Wagstaff, J., Gauler, T. C., Ueda, T., Xu, L-A., Waxman, I. M., Sharma, P. & 1 others, CheckMate 025 Investigators, Dec 2015, In : BJU international. 116, S5, p. 17 1 p.

Research output: Contribution to journalMeeting abstract

12 Citations (Scopus)